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1 Background 
1.1 Drug description 
Generic/Brand name/ATC code:  
Rituximab/Rituxan® (United States, Japan, Canada), MabThera® (rest of the 
world)/ L01X C02 
Developer/Company:  
Genentech, Inc., and Biogen Idec. co-market MabThera® in the United 
States. Chugai Pharmaceutical and Zenyaku Kogyo Co. Ltd. co-market 
MabThera® in Japan. Hoffmann-La Roche Ltd. markets MabThera® in the 
rest of the world [1].  
Description: 
Rituximab belongs to the pharmacotherapeutic group of antineoplastic 
agents and monoclonal antibodies [2]. 
Rituximab is a chimeric murine/human anti-CD20 monoclonal antibody 
targeted against the cluster of differentiation (CD) 20 antigen expressed on 
the surface of human B-cells. By binding to the CD20 antigen it promotes 
antibody-dependent cell-mediated cytotoxicity and complement-dependent 
cytotoxicity and induces lysis and apoptosis of normal and malignant hu-
man B- cells. Furthermore, it sensitises malignant B-cells to the cytotoxic ef-
fect of chemotherapy [2, 3].  
Administration:  
Six treatment cycles of rituximab are administered in combination with 
fludarabine and cyclophosphamide at intervals of 28 days (= 1 cycle). Ri-
tuximab is administered only once at the beginning of every cycle with an 
initial starting dose of 375mg/m2 body surface area (BSA) intravenously (iv) 
(cycle 1), followed by 500mg/m2 iv (cycle 2-6) [2]. 
1.2 Indication 
Rituximab in combination with chemotherapy is indicated for the first and 
second-line treatment of patients with CD20+ chronic lymphocytic leukae-
mia (CLL) [2].  
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and apoptosis of normal 
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1.3 Burden of disease 
CLL belongs to the entity of indolent B-cell non-Hodgkin lymphomas 
(NHL) and is the most common adult leukaemia in the Western World, ac-
counting for approximately 30% of all leukaemias. The vast majority of pa-
tients that is 70% are older than 65 years when diagnosed with CLL [4], cor-
responding to a median age of 72 years at diagnosis [4]. Men are affected 
twice as often as women [5, 6] and the median age of death is 79 years [4]. 
Risk factors for developing CLL include older age, male sex, white ethnicity, 
family history of CLL or other blood and bone marrow cancers and exposure 
to certain chemicals, such as herbicides and insecticides [7].  
In the majority of cases CLL is diagnosed incidentally by routine complete 
blood count examination. Most patients are asymptomatic at the time of di-
agnosis. The most common symptom is lymphadenopathy, followed by so 
called “B” symptoms, including fever, night sweats and weight loss. The life 
expectancy of patients with early stage disease at diagnosis is greater than 
ten years but decreases with advanced disease at diagnosis to a median sur-
vival of less than one year [8, 9]. 
There are two classification systems for the clinical staging of CLL, depend-
ing on standard laboratory tests and physical examination, including the Rai 
classification and the Binet staging system. The Rai classification distin-
guishes low (formerly Rai stage 0), intermediate (formerly Rai stage I or II) 
and high (formerly Rai stage IV and V) risk disease, whereas the Binet stag-
ing is subdivided into stage A, B and C (see Table 1) [10, 11].  
Table 1: Binet staging system for CLL (from [4]) 
Binet 
stage 
Clinical features Median survival 
(years) 
A Fewer than 3 areas of lymphadenopathy, 
no anaemia or thrombocytopenia 
12 
B More than 3 involved node areas or 
thrombocytopenia 
7 
C Haemoglobin >100g/L, platelets <100 x 
10g/L 
2-4 
 
Besides clinical staging, several other markers can be used as predicting fac-
tors. For example, cytogenetic abnormalities detected by fluorescence-in situ 
hybridisation are found in about 80% of all CLL patients [12, 13]. The most 
common one, that is deletion (del) 13q (in about 55%), is associated with a 
favourable prognosis whereas del17p and del11q are high-risk features pre-
dictive of disease progression [12, 13]. Also, patients with unmutated immu-
noglobulin variable region heavy chains (IGHV) have a shorter survival and 
a higher risk of relapse after initial therapy [13, 14]. Further factors related 
to poor prognosis are high serum levels of beta-2-microglobulin and high 
levels of ZAP-70 (zeta-chain associated protein kinase 70) and CD38 expres-
sion [10, 12-14]. 
The initiation of treatment is not recommended for asymptomatic early-
stage disease (Rai 0, Binet A). In these patients a watch-and-wait strategy 
CLL is the most common 
leukaemia in 
industrialised countries, 
and affects mainly 
patients aged ≥65 years 
the majority of patients 
is asymptomatic at 
diagnosis; symptoms 
may be 
lymphadenopathy and 
“B” symptoms  
diagnosis requires B 
lymphocytosis ≥5.0 x 
109/L in the peripheral 
blood for ≥ 3 months  
clinical staging depends 
on standard laboratory 
tests and physical 
examination 
advanced disease stage, 
short lymphocyte 
doubling time, etc. 
worsen the prognosis 
initiation of treatment 
depends on clinical 
staging; adenopathy, 
hepatosplenomegaly, 
autoimmune 
cytopenias, and marrow 
failure require 
treatment 
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with controls of blood cell counts and clinical examination every three to six 
months is recommended until disease progression. In patients with interme-
diate and high risk disease, according to the Rai classification as well as pa-
tients with Binet stage B or C disease, the initiation of treatment is recom-
mended, whereas some patients with intermediate disease or Binet stage B 
might as well be monitored until disease progresses [10, 11]. Disease pro-
gression requiring treatment is based on certain criteria, such as increasing 
adenopathy, hepatosplenomegaly, development of auto-immune cytopenias, 
and marrow failure [5, 11]. 
In Austria, no data are available for specific types of leukaemia, but the 
overall incidence of all forms of leukaemia (C91-C95 according to the World 
Health Organization’s International Classification of Diseases – 10) was 890 
and 740 people died in 2008 [6]. The incidence of CLL in Austria is ex-
pected to rise in the future due to an increasing elderly stratum of the popu-
lation. 
1.4 Current treatment options 
Patients diagnosed with CLL at an early stage should be observed only, 
whereas therapy should be initiated in patients with symptomatic disease, 
rapid disease progression, bulky lymphadenopathy and/or splenomegaly [4]. 
There are various treatment options for CLL depending on disease stage, pa-
tient’s age, presence of cytogenetic lesions, concomitant diseases and – in se-
cond line therapy – duration of response [15].  
Just briefly, either participation in a clinical trial or fludarabine-based ther-
apies, foremost fludarabine plus rituximab (FR), or fludarabine, cyclophos-
phamide and rituximab (R-FC) are increasingly recommended as 1st-line 
therapy for younger and fit patients [4, 12, 16], whereas chlorambucil is pre-
ferred for older patients with comorbidities [17]  
Several treatment options are available for patients with relapsed disease 
(=progressive disease after either complete or partial response for 
≥6months); one recommendation is to re-treat them with the initial therapy. 
For patients with refractory disease (=either no response, or disease pro-
gression within <6 months), chemotherapy is indicated but it is unclear 
which regimen should be used [18]. 
1.5 Current regulatory status 
Rituximab (MabThera®) is approved by the European Medicines Agency 
(EMA) [2] for  
 Non-Hodgkin’s lymphoma (NHL) (first approval was granted in 1998 
with subsequent extensions of indication), 
 for the treatment of previously untreated patients with stage III-IV 
follicular lymphoma in combination with chemotherapy. 
 as maintenance therapy for the treatment of follicular lymphoma 
patients responding to induction therapy. 
incidence of CLL in 
Austria is increasing 
several treatment 
options for first- and 
second-line therapy 
 1st-line: R-FC for 
younger and fit patients, 
chlorambucil for older 
patients with 
comorbidities 
relapsed patients: 
retreatment with initial 
therapy 
refractory patients: 
chemotherapy 
EMA approval for 
untreated and 
previously treated CLL 
patients  
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 as mono-therapy for treatment of patients with stage III-IV follicu-
lar lymphoma who are chemo-resistant or are in their second or 
subsequent relapse after chemotherapy. 
 for the treatment of patients with CD20 positive diffuse large B cell 
non-Hodgkin’s lymphoma in combination with CHOP (cyclophos-
phamide, doxorubicin, vincristine, prednisolone) chemotherapy. 
 CLL 
 in combination with chemotherapy for the treatment of patients 
with previously untreated (licensed January 2009) and re-
lapsed/refractory CLL (July 2009).  
 
 Rheumatoid arthritis (RA) 
in combination with methotrexate for the treatment of adult pa-
tients with severe active rheumatoid arthritis who have had an in-
adequate response or intolerance to other disease-modifying anti-
rheumatic drugs including one or more tumour necrosis factor in-
hibitor therapies (June 2006). 
 
Rituximab (Rituxan®) is approved by the United States Food and Drug Ad-
ministration (FDA) for 
 Non-Hodgkin's Lymphoma (NHL)  
 RA in combination with methotrexate in adult patients with moder-
ately to severely-active RA who have inadequate response to one or 
more tumour necrosis factor antagonist therapies  
 Wegener's Granulomatosis and Microscopic Polyangiitis 
 CLL in combination with fludarabine and cyclophosphamide (FC), 
for the treatment of patients with previously untreated and previously 
treated CD20-positive CLL since January 2011 [19]. 
1.6 Treatment costs 
In Austria, rituximab is marketed by Roche Austria, Vienna. One package of 
100mg rituximab (10mg/ml) concentrate for solution for infusion consisting 
of two single-use vials is € 616.15. In addition, one package of 500mg rituxi-
mab (10mg/ml) concentrate for solution for infusion containing one single-
use vial is € 1,492.75 [20]. 
Assuming an average body surface area, based on height and weight, of 1.7 
m² for both men and women, total treatment costs for the recommended ri-
tuximab regimen can be estimated. The first cycle of rituximab infusion 
would be € 2,109, followed by € 2,725 for cycle two to six (assuming that two 
packages containing two 100mg vials are used) which would add up to total 
treatment costs of € 15,734 in addition to chemotherapy, corresponding to 
monthly treatment costs of about € 2,600.- 
FDA approval for 
previously treated and 
untreated patients in 
combination with FC 
total costs of € 15,700 in 
addition to 
chemotherapy 
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2 Evidence 
A literature search was conducted on 2nd of August 2011 in four databases 
(EMBASE, Ovid, Cochrane Library and the CRD Database). After removal 
of duplicates, 340 references were found for 1st-line therapy and 180 for 2nd-
line therapy. 
Only results of randomized controlled trials (RCTs) were included, yielding 
three relevant references reporting results of two RCTs [21-23]. Three stud-
ies [24-26] were excluded, because one was not powered to detect clinically 
significant differences between treatment arms and did not present statisti-
cal comparisons [25], whereas the other one, only published as abstract, in-
vestigated treatment in a heterogeneous population of treatment- naïve and 
minimally treated patients [24]. The third study was excluded, because trial 
recruitment was stopped due to excess mortality in the comparator group 
[26]. 
In comparison to our initial HSS report [27], no further RCTs were in-
cluded, but both studies have been fully published in the meantime and 
long-term results have become available.  
 
two phase III studies 
now fully published  
CLL is biologically and in 
its clinical course 
heterogeneous 
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2.1 Efficacy and safety - RCTs 
Table 2: Phase III studies of rituximab for the first- and second-line treatment of CLL  
Reference  Hallek et al., CLL-8 [21, 22] Robak et al. , REACH trial [23] 
Sponsor Hoffmann-La Roche Hoffmann-La Roche 
Country central study office: Germany 
190 study centres in 11 countries 
central study office: Poland 
88 study centres in 18 countries 
Design randomised, open-label, multicentre, phase 3 study randomised, multicentre, open-label, phase III 
Hypothesis superiority superiority 
Number of patients  I 408 vs C 409 I 276 vs C 276 
Treatment   
Intervention 375mg/m2 (d0 in 1st cycle) - 500mg/m2 (d1 in 2nd – 6th cycle) ri-
tuximab iv  +25mg/m2/d fludarabine + 250mg/m2 (d1-3) cyclo-
phosphamide 
375mg/m2 - 500mg/m2 (d1) rituximab + 25mg/m2/d fludarabine + 
250mg/m2(d1-3) cyclophosphamide  
 
Control 25mg/m2/d fludarabine + 250mg/m2 (d1-3) cyclophosphamide 25mg/m2/d fludarabine + 250mg/m2 (d1-3) cyclophosphamide 
Inclusion criteria untreated, active CLL and good physical fitness (Cumulative 
illness rating scale ≤6), Binet stage C or with confirmed active 
disease Binet stages A or B, ECOG PS 0-1 
previously treated, CD20+ CLL, one prior line of therapy (single-agent 
chlorambucil (±prednisone/prednisolone), single-agent fludarabine 
(or other nucleoside analogue), or an alkylator containing combina-
tion regimen, but not an alkylator/nucleoside analog). Patients could 
be sensitive or refractory to prior alkylating agents but had to be sen-
sitive to fludarabine (defined as achieving a response that lasted ≥6 
months). Prior treatment with interferon, rituximab, other mono-
clonal antibodies, or stem-cell transplantation was not permitted. 
ECOG PS ≤1, life expectancy of more than 6 months 
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Participants  
characteristics 
  
Median age (years;  (range)) I 61 (30-80) vs  C 61 (36-81) I 63 (35 -83) vs C 62 (35 -81) 
≥65 years (%) I 31 vs C 29 I 42 vs C 44 
Men (%) I 74 vs C 74 I 68 vs C 66 
Binet stage A (%) I 4 vs C 5 I 9 vs C 11 
Binet stage B (%) I 64 vs C 63 I 60 vs C 58 
Binet stage C (%) I 31 vs C 31 I 31 vs C 31 
ECOG PS 0 (%) I 56 vs C 58  I 61 vs C 59 
Presence of B-symptoms (%) I 41 vs C 49 I 26 vs C31 
IGHV unmutated (%) I 63 vs C 63 I 61 vs C 65 
Del(13q) (%) I 54 vs C 60 I 56 vs C 60 
Del(11q) (%) I 27 vs C 22 I21 vs C22 
Del(17p) (%) I 7 vs C 10 I 7 vs C 9 
Trisomy 12 (%) I 10 vs C 14 I 11 vs C 15 
Follow-up NA 25 months 
OS   
Median (months) NA I NR vs C 52 (p=0.287) 
HR 0.67 (95%CI 0.48 – 0.92; p=0.012) 0.83 (95%CI 0.59 – 1.17; p=0.287) 
PFS (primary endpoint) (primary endpoint) 
Median (months)  I 51.8 vs. C 32.8 (p<0.0001) I 27.0 vs C 21.9 (p<0.0218)* 
HR 0.56 (95%CI 0.46 – 0.69; p<0.0001) 0.76 (95%CI  0.60 – 0.96; p<0.22) 
Horizon Scanning in Oncology 
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Tumour response   
ORR (%) I 90 vs C 80 (p<0.0001) I 61 vs C 49 (p=0.0048)* 
CR (%) I 44 vs C 22 (p<0.0001) I 9  vs C 3 (p=0.0046) 
QoL EORTC C30 questionnaire at 3 and 6 months: no difference in 
global health status, functional scales and symptom scales, 
dyspnoea score: I 18 vs C 23, p=0.023; at 12, 24 and 36 months 
follow-up: no difference 
FACT-G: no difference between treatment arms 
Adverse events according to NCI CTC v 2.0 
Any grade  I C  I C 
Overall  NA NA  99 96 
Hematologic  NA NA  NA NA 
Non-hematologic  NA NA Nausea 
Vomiting 
Pyrexia 
Fatigue 
Asthenia 
Chills 
Constipation 
Diarrhoea 
Cough 
Headache 
40 
21 
25 
16 
10 
15 
15 
12 
12 
9 
35 
19 
15 
17 
11 
2 
11 
12 
9 
11 
Grade ≥3  I C   I C 
Overall (%)  76 63   80 74 
Hematologic (%) Haematologic toxicity 
Neutropenia 
Leucocytopenia 
Thrombocytopenia 
Anaemia 
Autoimmune-haemolytic 
anaemia 
56 
34 
24 
7 
5 
<1 
40 
21 
12 
11 
7 
1 
Neutropenia 
Febrile neutropenia 
Anaemia 
Thrombocytopenia 
Granulocytopenia 
Pancytopenia 
42 
12 
12 
9 
7 
3 
40 
12 
13 
11 
4 
5 
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Non-hematologic (%) Infections (overall) 
Bacterial infections 
Tumour lyses syndrome 
Cytokine release syndrome 
25 
3 
<1 
<1 
21 
1 
<1 
0 
Pneumonia 
Hepatitis B 
5 
1.8 
6 
0 
Deaths associated with AEs (%)  2 3  14 10 
AEs leading to discontinuation  NA NA  26 25 
Notes In January, 2008, the pre-planned interim analysis showed a 
significant difference in the primary efficacy analysis and the 
study was formally ended. At this point, all patients had been 
enrolled and completed treatment. 
More patients started a subsequent treatment for CLL in the C arm 
(=69%) than in the I arm (=47%) 
I = intervention, C = control, NR= not reached, NA = not available, NCI CTC = National Cancer Institute Common Toxicity Criteria, CI = confidence interval, HR =hazard ratio, 
ORR = overall response rate, QoL = quality of life, AE= adverse event, ECOG PS = Eastern Cooperative Oncology Group Performance Status, EORTC C30 = European Or-
ganisation for Research and Treatment of Cancer Quality of Life Questionnaire, FACT-G= Functional Assessment of Cancer Therapy – General, OS =overall survival, PFS = 
progression-free survival, Cumulative illness rating scale = a scale classifying co-morbidities by organ systems, grading each condition from 0 (no problem) to 4 (severely inca-
pacitating or life-threatening condition) [28].  
 
*results from independent review committee assessments
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Published results of two randomised trials were found, one assessing ritux-
mab as 1st- line therapy [21, 22] and the other evaluating rituximab in previ-
ously treated patients [23].  
1st-line: 
Hallek et al. [21] compared R-FC to FC only in overall 817 patients. The 
study population consisted of mainly younger patients (29% of the patients 
were ≥65 years) with good performance status. Previous results of an in-
terim analysis at a median follow-up of 20.7 months showed that progres-
sion-free survival (PFS), the primary outcome, was 39.8 months for the R-
FC group and 32.2 months for the FC group (p<0.001) [29]. In the pub-
lished article [21], no information about the median follow-up is provided, 
but the results at 3 years after randomisation showed also improved results 
for the chemo-immunotherapy group (median OS I 51.8 months vs C 32.8 
months), yielding a hazard ratio of 0.56 (p<0.0001). A subgroup analysis 
produced similar findings for most prognostic subgroups, but results were 
not statistically significant for patients with Binet stage A or C and for indi-
viduals without genetic abnormalities. In contrast, however, several other 
documents (e.g. EMA’s European Public Assessment Report) report im-
proved outcomes in PFS also for other disease stages [29, 30]. OS showed 
also superior results overall, because the risk of death was reduced by 33% 
for patients treated with R-FC. Identical outcomes were observed for only 
some subgroups, that is patients with Binet stage B, del(13q), del(11q) and 
unmutated IGHV. It should be mentioned though that these findings might 
have been confounded since study treatment was stopped in patients with 
stable or progressive disease and a new therapy was started based on physi-
cians’ choice. Even though ORR, which is the sum of patients with partial 
and complete responses, was high, 10% of patients in the R-FC group and 
20% of patients in the FC group received treatments other than the study 
therapy, a fact which could have influenced OS. Of note, however, of the 
90% of patients in the R-FC group, a complete response was achieved in 
44%, in comparison to 22% in the comparator group. Based on these find-
ings the study was ended at the pre-planned interim analysis in January 
2008.  
 
In terms of AEs, any grade 3 or 4 side effects as well as haematological AEs 
overall and more specifically, neutropenia and leucocytopenia occurred sig-
nificantly more frequent in the combination arm. The authors additionally 
analysed toxicities according to age groups and reported that older patients 
(i.e. ≥65years) experienced side-effects more frequently than younger ones, 
due to haematological AEs as well as due to bacterial infections. The overall 
rate of infections, in contrast, did not differ, possibly, because granulocyte-
colony stimulating factor was given more frequently in the chemo-
immunotherapy group. Some results for QoL are presented as abstract, 
where no differences were found between the two groups; only dyspnoea 
scores showed favourable results for the R-FC group at 3 and 6 months [22]. 
 
 
 
 
 
PFS, OS and ORR 
significantly improved 
but OS possibly 
influenced by 
subsequent therapy 
PFS: hazard ratio =0.56 
complete responses in 
44% of patients treated 
with R-FC 
R-FC in comparison to 
FC as 1st-line therapy 
AEs, foremost 
haematological, more 
frequent in rituximab 
arm 
more often in patients 
≥65 years 
no difference in QoL 
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2nd line: 
The study by Robak et al. [23] investigated R-FC in comparison to FC in 
552 previously treated CLL patients. One prior therapy was allowed but 1st-
line therapy with an alkylator/nucleoside analogue combination (e.g. fluda-
rabine + cyclophosphamide) as well as any previous monoclonal antibody 
was not allowed. Patients also had to be sensitive to fludarabine (defined as 
achieving a response that lasted ≥6 months) and about 55% of all patients 
were also sensitive to alkylating agents. Most patients had thus relapsed dis-
ease rather than refractory disease.  
PFS and ORR were significantly improved for the R-FC group by both the 
investigator assessment and the independent review committee assessment. 
However, the findings of these two assessments rather deviate, as the differ-
ence in median PFS was 10 months according to the investigator assessment 
and only 5.1 months according to the independent review committee as-
sessments. At least some of this difference can be explained, because the in-
vestigator assessment took place one year after the independent assessment 
[31]. The investigators furthermore observed a complete response in 24% of 
patients in the R-FC group in contrast to 9% by the IRCA. For OS no differ-
ence was found, but this has to be interpreted with caution due to immature 
data and ensuing therapies after study treatment discontinuation. QoL, sim-
ilarly to the 1st-line study, did not differ between groups.  
AEs of any grade as well as higher grade AEs, and fatal side-effects were 
more frequent in the R-FC group than in the FC only group. Even though 
no detailed numbers are provided, the authors mention that AEs were also 
more frequent and more severe in older patients.  
3 Commentary  
Rituximab is licensed in combination with chemotherapy for untreated and 
previously treated CLL patients. In Europe there is no specific chemother-
apy regimen to be combined with rituximab, whereas in the US it is defined. 
The FDA licensed it only in combination with FC and also several guide-
lines recommend rituximab in addition to FC [16, 28]. In this context it 
should be mentioned, that in both trials which had used R-FC regimens, the 
majority of patients were younger than 65 years and had a good performance 
status, thus reflecting the population which is eligible for fludarabine-based 
therapy in the first instance, but which is not representative for the average 
CLL patient. In addition, AEs were observed more frequently in older pa-
tients. Consequently, an assessment conducted by the National Institute for 
Health and Clinical Excellence (NICE) concluded that combination with 
other chemotherapeutic regimens cannot be recommended, especially not in 
addition to chlorambucil – a therapy which is used for patients with poor 
performance status and co-morbidities [29] (trials are currently on-going 
comparing chlorambucil to rituximab [32]). Several guidelines also take age, 
but foremost presence of comorbidities and performance status into account 
and tend to prefer R-FC for younger and fitter patients [12, 13, 16, 28].  
R-FC vs FC in previously 
treated patients 
prior R-FC therapy not 
allowed 
patients had to be 
fludarabine-sensitive 
PFS + ORR significantly 
improved 
differences between 
investigator assessment 
and independent review 
assessment 
no difference for OS and 
QoL 
FDA: rituximab only in 
combination with FC 
also some guidelines 
prefer this combination,  
for younger patients 
without comorbidities 
EMA approved 
rituximab for 1st -line 
therapy in combination 
with chemotherapy 
without further defining 
which one 
Horizon Scanning in Oncology 
14 LBI-HTA | 2011 
PFS, the primary outcome in both phase III studies, demonstrated better re-
sults for R-FC, yielding a risk reduction of progression by 44% in the 1st-line 
setting. The trial assessing R-FC in previously treated, but fludarabine-
sensitive patients, excluded individuals which had received prior treatment 
with, for example, R-FC. But, as already mentioned, R-FC is increasingly 
recommended as 1st-line therapy [12, 16, 28], especially for patients <70 
years and with good performance status – all characteristics the study popu-
lation showed. It therefore remains unclear if patients previously treated 
with R-FC will also benefit when re-treated with R-FC. Similar concerns 
were expressed by NICE, which, after appeals from several organisations 
(e.g the UK Chronic Lymphocytic Leukaemia Forum, British Society for 
Haematology), had to re-formulate its guidance [30]: Re-treatment with ri-
tuximab got only allowed either in the context of a clinical trial, at a dose 
lower than the dose currently licensed for CLL or in combination with 
chemotherapies other than FC [14]. In this context, it is also of interest, how 
ofatumumab, a monoclonal antibody also targeting CD20, which showed ac-
tivity in fludarabine-refractory patients, will compare to R-FC treatment in 
fludarabine-sensitive patients [13].  
Another topic of investigation is how to incorporate biomarkers (e.g. 
del(17p), unmutated IGVH) to guide treatment decisions [13]. Hallek et al. 
[21] for example suggest that patients with del(17p) might not benefit from 
R-FC treatment, but might profit from treatments such as stem cell trans-
plantation. Another not completely resolved question concerns the optimal 
dosage of rituximab. Even though the labelled dose which was also used in 
all of the trials mentioned above, is 375mg/m² in cycle 1, followed by 
500mg/m² for each subsequent cycle, some authors argue that differing 
schedules might be used [4] which might potentially decrease treatment 
costs. In the absence of trials which demonstrate efficacy of rituximab also at 
lower doses, changes are not yet indicated [4]. 
In terms of OS, data for previously treated patients were immature and did 
not show any difference between treatment arms. In the 1st –line setting, OS 
was significantly improved, but because patients, who either not-responded 
or progressed, received alternative therapies this result has to be interpreted 
with caution. However, the gain in PFS and the improved response rates, es-
pecially in the 1st-line setting suggest that a better OS in patients treated 
with rituximab is also likely. Nonetheless, these improvements did not 
translate into more favourable outcomes for QoL but, at least, QoL was not 
significantly compromised by the addition of rituximab - despite more fre-
quent AEs in the R-FC arm than in the FC arm only. Other regimens, such 
as FR or pentostatin+cyclophosphamide+rituximab might be less toxic, but 
final study results comparing these therapies to R-FC are still missing [13]. 
 
 
 
 
 
but 2nd-line study 
excluded patients 
previously treated with 
R-FC 
PFS improved in both, 1st 
and 2nd-line therapy 
R-FC increasingly used 
as 1st-line therapy, 
potential to benefit for 
patients re-treated with 
R-FC unclear 
 
 
biomarkers to guide 
treatment decisions? 
 
optimal dosage? 
 
 
 
 
 
OS in 1st-line setting 
improved, but might be 
distorted due to 
subsequent lines of 
therapy 
due to increases in PFS 
and ORR, prolongation 
of OS also likely 
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